תוצאת חיפוש

Cellular Phone Interference with Medical Instruments

David Adler, Yona Mahler, Avi Israeli

Medical Engineering Dept., and Administration, Hadassah-University Hospital, Ein Kerem, Jerusalem

Cellular telephones and other telecommunication equipment occasionally cause malfunctioning of medical equipment, including life-support equipment. We review such malfunctioning and relate it to Israeli and worldwide standards, analyzing the characteristics of the interference in terms of amplitude and frequency. The results of a controlled study of interference by cellular telephones and portable 2-way radios with medical devices in our clinical departments are also presented. The levels of background environmental electromagnetic noise at several sites in both Hadassah hospitals (Ein Karem and Mount Scopus) were measured, as well as signal levels of cellular telephones and other communication equipment at various distances and in various areas. We recommend 2 different levels of restrictions on the use of this equipment within the hospital.

These include prohibition of the use of wireless telecommunication equipment in intensive care areas and operating theaters. In all other areas it is recommended to turn off the cellular telephone within 1 meter of medical devices and not to transmit (but only to receive) calls with a portable 2-way radio within a 5 meter distance of medical devices.

Efficacy and Safety of Acarbose Treatment of Niddm

Julio Wainstein, Medinah Jedwab

Dept. of Medicine C and Diabetes Unit, Wolfson Medical Center, Holon

An uncontrolled multicenter study of the efficacy and safety of treatment of diabetes with acarbose was conducted on 169 NIDDM patients in 12 medical centers in Israel. Acarbose was administered for 19 weeks, and the patients were followed for an additional 12 weeks. A substantial decrease in HbA1c levels from 8.5% to 7.5% (p<0.001) and in postprandial serum glucose levels from 283.6 mg/dl to 248.5 mg/dl (p<0.01) was seen during treatment. On follow-up, HbA1c levels increased by 0.45% and postprandial serum glucose rebounded from 256.4 mg/dl to 287.9 mg/dl. Acarbose was shown to be effective in treating NIDDM and to be safe and well-tolerated.

Ovarian Cancer In Israel, 1960-1989

Shlomo Mor-Yosef, Relo Avraham, Joseph G. Schenker

Dept. of Obstetrics and Gynecology, Hadassah-University Hospital, Ein Kerem, Jerusalem

In Israel ovarian cancer ranks among the most common malignant diseases in women. It is also one of the main causes of death from cancer in females in this country. Our population is composed of immigrants from diverse social, cultural, and geographical backgrounds, and only a sector of the inhabitants, mainly the younger generation, is Israeli-born. This study evaluates the trends of epidemiological and clinical data on ovarian cancer during 3 decades, 1960-1989, and includes a total of 5,786 cases of ovarian cancer. Information was obtained from the Central Israel Cancer Registry of the Ministry of Health and from the Central Bureau of Statistics. The incidence was stable during the survey period and was about 15-17/100,000 in women over the age of 15. Most (90%) were diagnosed over the age of 40. In women of European/American origin the incidence of ovarian cancer is 3 times greater than in women of Asian/African origin. The rate in the Israeli-born is between those of the other 2 groups, but closer to that of the European/American group. Over 70% were diagnosed with advanced disease (stage III-IV).

Prognosis improved during the period of the study: 5-year survival was 19% in the early 60's and 31% in the 80's. During the last decade of the survey improvement was mainly in 2-year survival (from 38.5% to 60%).